Want to see POM full AI Analyst Report?
POM Stock Chart & Stats
$0.94
--
Market closed
$0.94
--
Day’s Range― - ―
52-Week Range$0.69 - $385.80
Previous CloseN/A
VolumeN/A
Average Volume (3M)3.27M
Market Cap
$5.40M
Enterprise Value$10.00T>
Total Cash (Recent Filing)$1.86M
Total Debt (Recent Filing)$66.36M
Price to Earnings (P/E)―
Beta2.74
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,576,092
10 Day Avg. Volume9,779,482
30 Day Avg. Volume3,265,986
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)-0.26
Price to Sales (P/S)0.30
P/FCF Ratio-0.80
Enterprise Value/Market Cap93.50M
Enterprise Value/Revenue1.46M
Enterprise Value/Gross Profit12.54M
Enterprise Value/Ebitda-1.98M
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained revenue expansion indicates that PomDoctor is increasing demand for its offerings and broadening commercial reach. Although growth has not yet produced profits, a larger revenue base can support operating leverage, deepen customer relationships, and provide a foundation for scaling healthcare services over the next several quarters.
Diversified Revenue ModelA multi-tier revenue model reduces dependence on a single customer or service channel and creates several paths to monetization. Subscription, enterprise, and data offerings could add recurring or higher-value revenue alongside the existing business, supporting greater resilience and broader institutional relationships over time.
Integrated AI Healthcare PlatformIntegrating data collection, artificial intelligence, clinical services, and payment capabilities can create reinforcing operating advantages as usage generates more information and improves personalization. If execution continues, the connected ecosystem may strengthen engagement, expand service value, and make the platform harder to replicate.
Bears Say
Stressed Balance SheetPersistent negative equity and rising debt materially constrain financial flexibility and increase solvency pressure. A relatively small asset base compared with debt leaves less protection against operating setbacks, while leverage can restrict investment capacity and make future funding or refinancing more consequential for shareholders.
Severe Cash BurnConsistently negative cash generation means the company is not currently funding operations internally, and the sharp 2025 deterioration increases reliance on outside financing. Continued cash burn can accelerate dilution or borrowing needs, reduce strategic flexibility, and make growth harder to sustain without improved economics.
Nasdaq Listing RiskThe Nasdaq delisting determination creates a structural trading and capital-markets risk rather than a temporary sentiment issue. If the appeal fails or compliance cannot be restored, reduced U.S. market access could impair visibility, liquidity, investor participation, and the company’s ability to use its listing to support financing.
PomDoctor Ltd. Unsponsored ADR News
POM FAQ
What was PomDoctor Ltd. Unsponsored ADR’s price range in the past 12 months?
PomDoctor Ltd. Unsponsored ADR lowest stock price was $0.69 and its highest was $385.80 in the past 12 months.
What is PomDoctor Ltd. Unsponsored ADR’s market cap?
PomDoctor Ltd. Unsponsored ADR’s market cap is $5.40M.
When is PomDoctor Ltd. Unsponsored ADR’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were PomDoctor Ltd. Unsponsored ADR’s earnings last quarter?
Currently, no data Available
Is PomDoctor Ltd. Unsponsored ADR overvalued?
According to Wall Street analysts PomDoctor Ltd. Unsponsored ADR’s price is currently Overvalued.
Does PomDoctor Ltd. Unsponsored ADR pay dividends?
PomDoctor Ltd. Unsponsored ADR does not currently pay dividends.
What is PomDoctor Ltd. Unsponsored ADR’s EPS estimate?
PomDoctor Ltd. Unsponsored ADR’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PomDoctor Ltd. Unsponsored ADR have?
PomDoctor Ltd. Unsponsored ADR has 2,576,092 shares outstanding.
What happened to PomDoctor Ltd. Unsponsored ADR’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of PomDoctor Ltd. Unsponsored ADR?
Currently, no hedge funds are holding shares in POM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PomDoctor Ltd. Unsponsored ADR
Pomdoctor Limited, operating through its various divisions, runs an e-commerce platform for the direct sale of pharmaceutical products to consumers. The company is actively developing an online healthcare services platform specifically designed for managing long-term illnesses within the Chinese market. Its primary emphasis is on chronic disease care and pharmaceutical provision, facilitating a digital portal that connects patients with medical professionals and essential medications. Pomdoctor's operations largely encompass both a virtual hospital model and a comprehensive pharmaceutical supply chain, thus linking individual users, pharmacies, distributors, medical experts, and other healthcare stakeholders. This enterprise was established in 2010 and is headquartered in Guangzhou, China.
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
0.17% Other Institutional Investors
99.83% Public Companies and
Individual Investors